Bifogade filer
20241121_Isofol _PM_Modelle study_Final
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, November 21, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the investigator-initiated Modelle study, evaluating the effect of the drug candidate arfolitixorin at tissue level, has been published in the scientific journal BJC Reports.
The information in the press release is intended for investors.
Modelle is an investigator-initiated study conducted at Sahlgrenska University Hospital in collaboration with Norrlands University Hospital and co-financed by Isofol. The study included 30 patients, and the purpose was to investigate the effect of Isofol’s drug candidate arfolitixorin compared to leucovorin, in combination with 5-FU in patients with colorectal cancer that had metastasized to the liver, as well as to evaluate the concentration of active substance each drug achieves in the liver and metastatic tissue.
The study evaluated different doses of arfolitixorin and its ability to enhance the tumor-inhibiting effect of 5-FU-based chemotherapy. The effect was measured as inhibition of thymidylate synthase (TS), an enzyme that drives tumor cell growth and is thus an important target in cancer treatment.
The results showed that giving arfolitixorin resulted in significantly higher concentrations of the active substance in liver metastatic tissue compared to the given dose of the standard of care treatment leucovorin. Further, an increased inhibition of TS was shown with the higher of two doses of arfolitixorin.
“The Modelle study, among other interesting findings, indicates a dose-dependent inhibition of TS in patients’ liver metastases and complements other pre-clinical studies where surrogate markers have been used to measure inhibition of TS. The findings are yet another piece of the puzzle supporting the dose-response relationship of arfolitixorin and the hypothesis we are working with for the continued development of arfolitixorin”, says Petter Segelman Lindqvist, CEO at Isofol.
The title of the publication is: "Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10- methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial" and is available via the link: https://doi.org/10.1038/s44276-024-00111-4
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact persons set out above, at 15:25 CET on November 21, 2024.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.